Clinical progress of engineered cellular immunotherapies for autoimmunity
- 16 February 2026
- journal article
- review article
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (4) , 547-562
Abstract
Cellular immunotherapies encompass a broad and rapidly developing group of treatments comprising expanded and/or genetically engineered immune cells, which use the specific properties of human immune cells to counteract human immune-mediated disease. Initially approved for cancers of the B cell lineage, a growing arsenal of cellular immunotherapies are being applied to autoimmune diseases, including chimeric antigen receptor (CAR) T cells, chimeric autoantibody receptor T cells, regulatory T cells and CAR-engineered innate immune cells. These approaches represent a major shift in the way scientists and physicians pursue the treatment of human disease compared to standard immunosuppressive therapies. Here, we review the clinical progress of engineered cellular immunotherapies for autoimmunity. We focus on how antigenic target, engineered cell type, CAR design and treatment regimens affect the therapeutic efficacy and safety of these treatments and how these emerging clinical data can inform future directions in the field.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR082675)
- Myasthenia Gravis Foundation of America
- Japan Society for the Promotion of Science (JP22H04994)
- Japan Agency for Medical Research and Development (JP21ek0410058)
- Japan Agency for Medical Research and Development (JP21gm1010001)
- Japan Agency for Medical Research and Development (JP24ek0109728)
- National Cancer Institute (OT2CA278700)
- National Heart, Lung, and Blood Institute (UG1HL108945)
This publication has 166 references indexed in Scilit:
- Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia GravisAnnals of Clinical and Translational Neurology, 2025
- Autologous CD19‐Targeting CAR T Cells in a Patient With Refractory Juvenile DermatomyositisArthritis & Rheumatology, 2024
- T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell TherapyJAMA Oncology, 2024
- Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignanciesCancer Immunology, Immunotherapy, 2023
- Identification of Covariates Modulating B‐Cell Repopulation Kinetics in Subjects Receiving Rituximab TreatmentArthritis & Rheumatology, 2023
- CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeJAMA, 2023
- A Consideration of Fixed Dosing Versus Body Size‐Based Dosing Strategies for Chimeric Antigen Receptor T‐Cell TherapiesClinical Pharmacology in Drug Development, 2022
- Utilization of MG‐ADL in myasthenia gravis clinical research and careMuscle & Nerve, 2022
- B cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis & Rheumatism, 2011
- Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapyArthritis & Rheumatism, 2007